Amarin Corp Plc (AMRN)

[Biobillionair]

Jas- Thanks...but if Lavin had a substantial point the patent would not be granted...again means nothing to Amarins argument.

This one has some substance. Amarin moved to exclude testimony regarding Dr. Lavin. I don't have that testimony but it is clear to me that it relates to the patent office: what the patent office wss told when the patent was issued, as compared to what the parties now know, about obviousness. In sum, the generics are allowed to present additional evidence of "obviousness" which gives them a higher chance of winning that argument.

What’s gain in ruling today? Knowledge that the defendants don’t have a clue on how to defend inducement or prove obviousness in light of R-I results.

Thanks for your pro-views.

BB